Table 2.
Combination study of CBFbeta inhibitor with conventional chemotherapeutic drugs in canine OSA cell lines.
| CELL LINE | TREATMENT | PARAMETERS | CI VALUE | DRI VALUE | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dm | m | r | ED50 | ED75 | ED90 | ED95 | ED50 | ED75 | ED90 | ED95 | ||
| Abrams | DOX | 33.84 | 0.91 | 0.82 | 2.10 | 4.16 | 8.25 | 13.13 | ||||
| Carbo | 10.02 | 0.68 | 1.00 | 0.82 | 1.73 | 3.64 | 6.04 | |||||
| AI | 12.75 | 1.76 | 0.93 | 5.23 | 4.07 | 3.16 | 2.67 | |||||
| AI:DOX | 19.31 | 2.11 | 0.87 | 0.81 | 0.49 | 0.31 | 0.23 | |||||
| AI:Carbo | 14.63 | 1.25 | 0.96 | 1.41 | 0.82 | 0.59 | 0.54 | |||||
| D-17 | DOX | 35.84 | 0.83 | 0.99 | 1.80 | 2.55 | 3.60 | 4.55 | ||||
| Carbo | 56.57 | 1.52 | 0.97 | 1.81 | 1.77 | 1.74 | 1.72 | |||||
| AI | 18.75 | 3.48 | 0.93 | 2.99 | 1.95 | 1.27 | 0.95 | |||||
| AI:DOX | 23.85 | 1.12 | 0.98 | 0.79 | 0.82 | 1.08 | 1.44 | |||||
| AI:Carbo | 37.56 | 1.48 | 0.98 | 0.89 | 1.08 | 1.36 | 1.63 | |||||
| Gracie | DOX | 8.61 | 0.57 | 0.93 | 0.56 | 2.35 | 9.82 | 26.00 | ||||
| Carbo | 19.28 | 1.15 | 0.99 | 1.21 | 2.14 | 3.77 | 5.55 | |||||
| AI | 13.29 | 1.35 | 0.92 | 4.33 | 5.91 | 8.08 | 9.98 | |||||
| AI:DOX | 18.43 | 2.18 | 0.91 | 2.02 | 0.60 | 0.23 | 0.14 | |||||
| AI:Carbo | 19.06 | 2.85 | 0.93 | 0.96 | 0.56 | 0.33 | 0.23 | |||||
| HMPOS | DOX | 1.88 | 0.77 | 0.80 | 30.98 | 2.57 | 0.21 | 0.04 | ||||
| Carbo | 6.85 | 2.07 | 0.94 | 0.75 | 0.84 | 0.94 | 1.02 | |||||
| AI | 15.67 | 2.59 | 0.98 | 4.26 | 4.30 | 4.34 | 4.36 | |||||
| AI:DOX | 0.08 | 0.28 | 0.64 | 0.03 | 0.45 | 6.15 | 38.40 | |||||
| AI:Carbo | 12.87 | 2.64 | 0.96 | 1.58 | 1.43 | 1.29 | 1.21 | |||||
AI: AI-14-91, Dox: Doxorubicin, Carbo: Carboplatin, Dm: median-effect dose, m: slope, r: linear correlation coefficient of the Dm plot, (conformity), CI: Combination index (<1 synergism, 1 additive, >1 antagonism), DRI: dose-reduction index, ED: dose-effect levels of cell growth inhibition.